Carregant...
A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay
Predicting recurrence risk and chemotherapy benefit in early-stage breast cancer is challenging. The Oncotype DX gene assay is often used. Using a database of 221 patients a simple 2-rule model was developed and validated on an independent group of 319 patients. The model categorizes patients unlike...
Guardat en:
| Publicat a: | Clin Breast Cancer |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4847530/ https://ncbi.nlm.nih.gov/pubmed/26072275 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clbc.2015.04.006 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|